Fredrick Wigley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7545857/publications.pdf

Version: 2024-02-01

10	1,042	5	7
papers	citations	h-index	g-index
11	11	11	1327
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	10.7	754
2	Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis. Journal of Experimental Medicine, 1997, 185, 71-80.	8.5	198
3	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	1.9	51
4	Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. Journal of the American Academy of Dermatology, 2019, 80, 1449-1451.	1.2	21
5	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	1.0	7
6	Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis. Lancet Rheumatology, The, 2022, 4, e462-e464.	3.9	6
7	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2022, 74, 1300-1310.	3.4	4
8	Troponin elevation independently associates with mortality in systemic sclerosis. Clinical and Experimental Rheumatology, 0 , , .	0.8	1
9	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	1.9	O
10	Troponin elevation independently associates with mortality in systemic sclerosis Clinical and Experimental Rheumatology, 2022, , .	0.8	0